Oklahoma Medical Research Foundation
This study will compare starting Ocrevus Zunovo soon after an active episode of relapsing multiple sclerosis (MS) with starting it later. Researchers want to learn whether starting treatment sooner reduces the number of MS relapses over 18 months. They will also study changes in immune cells, blood markers, disability, and MRI scans. About 35 adults with relapsing MS will take part at Oklahoma Medical Research Foundation or Corewell Health West. One group will start Ocrevus Zunovo before leaving the clinic or hospital. The other group will start treatment later. Ocrevus Zunovo is given as an injection under the skin. Participants will have blood draws and follow-up visits for up to 18 months. Researchers will also review their medical records for relapses, steroid treatments, emergency department visits, and hospital stays. About 10 adults without MS will provide blood samples to help researchers compare immune cell measurements.
This prospective, open-label, controlled study will compare rapid initiation of Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with delayed initiation in adults with relapsing multiple sclerosis (MS). The primary objective is to compare annualized relapse rates over 18 months. Secondary assessments include changes in B- and T-cell populations and other blood biomarkers, disability scores, MRI findings, and health care use. Approximately 35 adults with relapsing MS will be enrolled at two sites. The rapid-initiation group will include approximately 18 participants recruited at Corewell He…
Participants With Relapsing Multiple Sclerosis (Rapid-Start and Delayed-Start Cohorts) Inclusion Criteria: * Age 18 years or older. * Diagnosis of relapsing-remitting multiple sclerosis according to the 2017 McDonald criteria. * At least one gadolinium-enhancing lesion on an MRI of the brain, cervical spine, or thoracic spine within 4 weeks of relapse or hospitalization. Exclusion Criteria: * Diagnosis of primary progressive multiple sclerosis. * Active hepatitis B. * Current pregnancy. * Allergy to gadolinium contrast or known allergy to ocrelizumab. * Unable to complete an MRI. * Contrai…
Arctuva estimate
Verify or correct the compensation shown for this listing.